ERBB2 and lung cancer: Oncogenic driver gene mutations, such as those in epidermal growth factor receptor (EGFR), KRAS, ALK, human epidermal growth factor receptor 2 (HER2), and mesenchymal-epithelial transition (MET), play essential roles in the initiation, progression, and clinical treatment of lung cancer.